Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company that develops differentiated and novel therapies to address the unmet medical needs of patients with cancer in the United ...

Vincerx Pharma, Inc. (VINC) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates ...

Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another high in ...

Vincerx Pharma Inc (NASDAQ:VINC) shares are trading lower by 9.7% to $0.81 during Friday’s session after the company priced an underwritten public offering, including 6 million shares of common stock ...

Estimated Earnings Per Share: Analysts projected a loss of $0.295 per share. Actual Earnings Per Share: VINC reported a loss of $0.23 per share, slightly better than estimates. Estimated Net Income: ...

In a turbulent market environment, Vincerx Pharma, Inc. (VINC) stock has reached its 52-week low, trading at $1.3. According to InvestingPro analysis, the company maintains a healthy current ratio of ...

As of February 12, 2023, the average one-year price target for Vincera Pharma is $8.77. The forecasts range from a low of $3.03 to a high of $21.00. The average price target represents an increase of ...